Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
The company will acquire ImCheck for €350m.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
